6,059 reports of this reaction
4.9% of all OCRELIZUMAB reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for OCRELIZUMAB, manufactured by Genentech, Inc.. There are 6,059 FDA adverse event reports linking OCRELIZUMAB to FATIGUE. This represents approximately 4.9% of all 123,105 adverse event reports for this drug.
OCRELIZUMAB has an overall safety score of 78 out of 100. Patients taking OCRELIZUMAB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among OCRELIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for OCRELIZUMAB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 6,059 FDA reports for OCRELIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 4.9% of all adverse event reports for OCRELIZUMAB, making it one of the most commonly reported side effect.
If you experience fatigue while taking OCRELIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.